Also, ApoE in HDL could act as a protective factor since AD patients present HDL with lower ApoE content (Pedrini et al., 2022), and in our previous study, we observed that subjects from an ICH-CAA cohort presented a higher ratio of ApoE/ApoC-III in HDL than controls which we hypothesized to be a defensive response against vascular Aβ deposition (Bonaterra-Pastra et al., 2021). This evidence concerns the gene APOE and Alzheimer disease.